Browsing Tag
Hippo pathway
2 posts
How oral Targeted Glue degraders could change dosing paradigms in cancer treatment
Discover how oral Targeted Glue degraders could transform cancer dosing strategies and reshape oncology treatment models. Read the full analysis.
Can ODM-212 validate TEAD inhibition as a viable oncology strategy in mesothelioma?
Can Orion Corporation’s ODM-212 prove TEAD inhibition works in mesothelioma? Discover what this FDA orphan designation really signals.